secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2025-07-31T23:59:59+00:00
Accession:  0001628280-25-036846
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crescent Biopharma Q2 net loss $21.8M; merger & $200M financing closed
----------------------------------------------------------------------

- Net loss $21.8M ($4.93/share) for Q2 2025; R&D $12.1M, G&A $8.9M.
- Cash $152.6M as of June 30, 2025, expected to fund operations through 2027.
- Completed merger with GlycoMimetics and closed $200M private financing.
- IND for CR-001 (PD-1 x VEGF bispecific) on track for Q4 2025; proof-of-concept data H2 2026.
- Adopted Executive Severance Plan with change-in-control benefits for executives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000162828025036846/0001628280-25-036846-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000162828025036846/cbio-20250729.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-036846

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer